Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

United BioPharma (6471)

TPEX
Currency in TWD
Disclaimer
27.00
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
27.0036.00
52 wk Range
0.0036.00
Prev. Close
32.6
Open
32
Day's Range
27-36
52 wk Range
0-0
Volume
0
Average Volume (3m)
72,549,983
1-Year Change
0%
Shares Outstanding
175,591,199
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about 6471?
Vote to see community's results!
or

United BioPharma Company Profile

United BioPharma, Inc. develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies in Taiwan. Its molecules product pipeline includes UB-421 for the treatment of AIDS; UB-621, an anti-herpes simplex virus mAb; UB-221, which is in phase I trial for the treatment of Chronic urticaria; UB-721 that is in process development for the treatment of autoimmune diseases; UB-923 that is in manufacturing process development for the treatment of non-hodgkin’s lymphoma, rheumatoid arthritis, etc.; UB-925, which is in process development stage for the treatment of gastric, colorectal, and non-small cell lung cancer; and UB-926 that is in process development stage for the treatment of breast cancer. The company’s biosimilars under development also comprise UB-921, which is in Phase I clinical trial for the treatment of breast cancer; and UB-922, which is in process development for the treatment of colorectal, brain, renal cell, and non-small cell cancers. It has a collaboration agreement with Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology for long-acting herpes treatment UB-621. United BioPharma, Inc. was founded in 2013 and is based in Taipei, Taiwan.

Employees
152
Market
Taiwan
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.